New Engineered Cell Therapy Enters First Human Trial for Type 1 Diabetes

GentiBio has dosed the first participant in POLARIS, a Phase 1 clinical trial testing GNTI-122, an engineered regulatory T cell therapy designed to preserve the body's natural insulin production in people recently diagnosed with Type 1 diabetes.

News report — unverified, pending corroboration

Evidence label explains the kind of source behind this article (for example peer-reviewed literature vs community video). It is not medical advice.

cure researchbeta cellsadvancements

Key takeaways

GNTI-122 is a single-dose, personalized cell therapy that works by engineering a patient's own immune cells to reduce insulin-destroying inflammation
The Phase 1 POLARIS trial is enrolling adults diagnosed with Type 1 diabetes within the past 120 days—a critical window when some insulin production may still be preserved
This is an early-stage study focused on safety and biological signals; it will take years to determine whether the therapy can meaningfully reduce or eliminate insulin dependence
The trial is taking place at 10 U.S. clinical sites with expertise in cell-based immunotherapies

A New Approach to Stopping Type 1 Diabetes Early

GentiBio, a clinical-stage biotechnology company, announced on March 18, 2026, that the first participant has received GNTI-122 in the POLARIS Phase 1 clinical trial. The therapy represents a novel approach: instead of replacing insulin or suppressing the entire immune system, GNTI-122 uses engineered regulatory T cells—specialized immune cells designed to stop the specific inflammation that destroys insulin-producing beta cells.

The therapy is autologous, meaning doctors extract and engineer each patient's own immune cells before returning them. The goal is to restore immune tolerance—essentially teaching the body's immune system to stop attacking its own insulin-producing cells.

Why Timing Matters

The POLARIS trial specifically enrolls adults diagnosed with Type 1 diabetes within 120 days of symptom onset. This timing is intentional: in the early weeks and months after diagnosis, many people retain some natural insulin production. By intervening at this critical window, researchers hope to preserve or restore the pancreas's remaining ability to make insulin.

The trial will evaluate the safety, tolerability, and key biomarkers that might signal whether the engineered cells are working to preserve insulin production. The first participant was dosed at the University of North Carolina, Chapel Hill, with enrollment continuing at nine other specialized clinical sites across the United States.

What This Trial Will and Won't Show

Phase 1 trials are early-stage studies designed primarily to test whether a therapy is safe and tolerable in humans. POLARIS will also look for biological signals—measurable evidence that the engineered cells are functioning as intended—but it is not yet designed to prove that GNTI-122 reduces insulin dependence.

It will take time and further research to determine whether this approach can meaningfully reduce or eliminate the need for insulin injections. Anyone interested in learning more about the trial or exploring whether they might qualify as a participant should speak with their healthcare provider.

Evidence label

Origin: prnewswire.com (News report). Evidence: News report — unverified, pending corroboration. Type1Cure is an information and intelligence hub, not a medical advice service. This article summarizes published research and does not provide diagnosis, treatment, or personal medical guidance. Always talk to your own care team before changing anything about your Type 1 diabetes management.

Type1Cure is an information and intelligence hub, not a medical advice service. This article summarizes published research and does not provide diagnosis, treatment, or personal medical guidance. Always talk to your own care team before changing anything about your Type 1 diabetes management.

More evidence-labeled coverage across the Type1Cure library.